首页|基于抗体分型的幽门螺杆菌四联疗法治疗效果观察

基于抗体分型的幽门螺杆菌四联疗法治疗效果观察

扫码查看
目的 基于幽门螺杆菌(Hp)抗体分型,观察Hp四联疗法的治疗效果。方法 选取2023年1月-2024年3月就诊于酒钢医院消化内科门诊14C尿素呼气试验阳性的Hp现症感染患者215例为病例组,依据Hp抗体分型分为Ⅰ型亚组146例和Ⅱ型亚组69例。另选取健康体检者122例为健康对照组。病例组采用四联疗法治疗,总疗程2周。治疗后4周,比较Ⅰ型亚组和Ⅱ型亚组14C尿素呼气试验转阴率,治疗前后Ⅰ型亚组、Ⅱ型亚组与健康对照组的胃肠激素[胃泌素-17(G-17)、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、胃蛋白酶原比值(PGR)]、炎性因子[白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]水平及不良反应。结果 治疗后4周,Ⅰ型亚组14C尿素呼气试验转阴率为80。82%(118/146),高于Ⅱ型亚组的72。46%(50/69),但差异无统计学意义(x2=1。916,P=0。166)。治疗前,Ⅰ型亚组和Ⅱ型亚组G-17、PGⅠ、PGⅡ、IL-6、hs-CRP水平高于健康对照组,PGR低于健康对照组,且Ⅰ型亚组G-17、PG Ⅰ、PGⅡ水平高于Ⅱ型亚组,PGR低于Ⅱ型亚组(p<0。01);治疗后4周,Ⅰ型亚组和Ⅱ型亚组G-17、PG Ⅰ、PGⅡ水平均降低,PGR均升高(P<0。05或P<0。01),但Ⅰ型亚组G-17、PG Ⅰ、PGⅡ水平和Ⅱ型亚组的PG Ⅱ水平仍高于健康对照组,Ⅰ型亚组的PGR仍低于健康对照组(P<0。05);Ⅱ型亚组的G-17、PG Ⅰ、PGR水平与健康对照组比较差异无统计学意义(P>0。05)。治疗前,Ⅰ型亚组和Ⅱ型亚组IL-6、hs-CRP水平高于健康对照组,且Ⅰ型亚组IL-6、hs-CRP水平高于Ⅱ型亚组(P<0。01);治疗后4周,Ⅰ型亚组和Ⅱ型亚组IL-6、hs-CRP水平低于治疗前,但高于健康对照组(P<0。01)。Ⅰ型亚组与Ⅱ型亚组不良反应总发生率比较差异无统计学意义(6。85%vs。5。80%,x2=0。085,P=0。770)。结论 不同抗体分型Hp对胃黏膜的损害程度不同,Ⅰ型菌株对患者胃黏膜损害更大,四联疗法对Ⅰ型Hp感染和Ⅱ型Hp感染的治疗效果均较好,且Ⅰ型感染14C尿素呼气试验转阴率略高于Ⅱ型Hp感染。
Observation of therapeutic effect of quadruple therapy of Helicobacter pylori based on antibody typing
Objective Based on Helicobacter pylori(Hp)antibody typing,the therapeutic effect of Hp quadruple therapy was observed.Methods A total of 215 patients with Hp infection who were admitted to the Gastroenterology Department of Jiugang Hospital from January 2023 to March 2024 with positive 14C urea breath test were selected as the case group,and were divided into type Ⅰ subgroup(146 cases)and type Ⅱ subgroup(69 cases)according to Hp antibody type.Another 122 healthy subjects were selected as healthy control group.The patients were treated with quadruple therapy for a total course of two weeks.Four weeks after treatment,the negative conversion rate of 14C urea breath test was compared between type Ⅰsubgroup and type Ⅱ subgroup.The levels of gastrointestinal hormones(G-17,PG Ⅰ,PG Ⅱ,PGR),inflammatory factors(IL-6,hs-CRP)before and after treatment,and adverse reactions in subgroups Ⅰ,Ⅱ and healthy control group were compared.Results At four weeks after treatment,the negative conversion rate of 14 C urea breath test in type Ⅰ subgroup was 80.82%(118/146),higher than 72.46%in type Ⅱ subgroup(50/69),but the difference was not statistically significant(x2=1.916,P=0.166).Before treatment,the levels of G-17,PG Ⅰ,PG Ⅱ,IL-6 and hs-CRP in type Ⅰ and type Ⅱsubgroups were higher than those in healthy control group,the PGR levels were lower than those in healthy control group,and the levels of G-17,PG Ⅰ,PG Ⅱ in type Ⅰ subgroup were higher than those in type Ⅱ subgroup,and the PGR levels were lower than those in type Ⅱ subgroup(P<0.01).Four weeks after treatment,the levels of G-17,PG Ⅰ and PG Ⅱ in type Ⅰsubgroup and type Ⅱ subgroup were decreased,and PGR were increased(P<0.05 or P<0.01),but the levels of G-17,PGⅠ,PG Ⅱ in type Ⅰ subgroup and PG Ⅱ in type Ⅱ subgroup were still higher than those in healthy control group,and the PGR in type Ⅰ subgroup was still lower than that in healthy control group(P<0.05).There was no significant difference in G-17,PG Ⅰ and PGR levels between type Ⅱ subgroup and healthy control group(P>0.05).Before treatment,the levels of IL-6 and hs-CRP in type Ⅰ subgroup and type Ⅱ subgroup were higher than those in healthy control group,and the levels of IL-6 and hs-CRP in type Ⅰ subgroup were higher than those in type Ⅱ subgroup(P<0.01).At four weeks after treatment,the levels of IL-6 and hs-CRP in type Ⅰ and type Ⅱ subgroups were lower than before treatment,but higher than those in healthy control group(P<0.01).There was no significant difference in the incidence of adverse reactions between type Ⅰ subgroup and type Ⅱ subgroup(6.85%vs.5.80%,x2=0.085,P=0.770).Conclusion Different antibody types of Hp had different damage degrees to gastric mucosa,and the type Ⅰ strain had greater damage to gastric mucosa.The treatment effect of quadruple therapy on type Ⅰ Hp infection and type Ⅱ Hp infection was better,and the negative conversion rate of 14C urea breath test for type Ⅰ infection was slightly higher than that for type Ⅱ Hp infection.

Helicobacter pylori infectionAntibody typeQuadruple therapyGastrointestinal hormoneInflammatory factor

毕胜飞、赵婧、马子豪、高学智、张辉、王仲玉、宋歌

展开 >

735100 甘肃省嘉峪关市,酒钢医院检验科

735100 甘肃省嘉峪关市,酒钢医院重症医学科

735100 甘肃省嘉峪关市,酒钢医院消化科

幽门螺杆菌感染 抗体分型 四联疗法 胃肠激素 炎性因子

2025

临床合理用药
河北省科学技术协会

临床合理用药

影响因子:0.799
ISSN:1374-3296
年,卷(期):2025.18(1)